NVAX Q3 2024 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$85M+283.0% YoY

Gross Profit

$24M28.3% margin

Operating Income

-$134M-158.6% margin

Net Income

-$121M-143.5% margin

EPS (Diluted)

$-0.76

QoQ Revenue Growth

-79.7%

Cash Flow

Operating Cash Flow

-$145M

Free Cash Flow

-$147M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$2.2B

Stockholders' Equity

-$526M

Cash & Equivalents

$574M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$85M	$22M	+283.0%
Gross Profit	$24M	-$77M	+131.1%
Operating Income	-$134M	-$126M	-6.7%
Net Income	-$121M	-$131M	+7.2%

Revenue Segments

Royalties and Other

$46M55%

Product

$38M45%

Geographic Segments

North America

$34M89%

Rest of the World

$3M8%

Europe

$1M3%